Clinical trials: EGFR Gene Mutation, open to volunteers
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Relapsed or Advanced Non-small Cell Lung Cancer
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the…
- Trial name
- NCT05503888
- Testing
- Almonertinib combined with SHR-1701, Almonertinib
- Volunteers
- 160 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
This study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or…
- Trial name
- NCT06956001
- Testing
- Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Allist Pharmaceuticals, Inc.
NSCLC, EGFR Activating Mutation
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.
- Trial name
- NCT05382728
- Testing
- TY-9591, Osimertinib
- Where
- 2 sites in China
- Volunteers
- 680 people
- Sponsor
- TYK Medicines, Inc
Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in…
- Conditions
- Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
- Trial name
- NCT07185997
- Testing
- Firmonertinib, EGFR-TKI inhibitor based on investigator's choice
- Where
- 141 sites in United States, Australia and 15 more
- Volunteers
- 480 people
- Sponsor
- ArriVent BioPharma, Inc.
NSCLC Stage IV, EGFR Gene Mutation
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.
- Trial name
- TROP-LUNG (NCT07548060)
- Testing
- sacituzumab tirumotecan
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
- Conditions
- Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
- Trial name
- NCT05503667
- Testing
- Furmonertinib, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
The goal of this adaptive, interventional study is to assess the efficacy and safety of osimertinib-based adaptive treatment based on ctDNA dynamic monitoring in locally advanced or metastatic EGFRm NSCLC participants with ctDNA…
- Trial name
- NCT07058519
- Testing
- Osimertinib-based adaptive treatment, Osimertinib 80 MG
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Disitamab Vedotin（RC48）combined with EGFR or HER2 TKIs in locally advanced or metastatic NSCLC Patients with HER2 Alterations.
- Conditions
- Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
- Trial name
- NCT06185400
- Testing
- Disitamab Vedotin, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib
- Volunteers
- 108 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
This is a single-arm, multicenter, open-label, phase Ⅱ exploratory clinical study, which plans to enroll 74 treatment-naive patients with EGFR-sensitive mutations (exon 19 deletion, exon 21 L858R mutation) and symptomatic brain…
- Trial name
- HOPE-WBRT (NCT07505173)
- Testing
- Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O, Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer, EGFR Gene Mutation
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
- Trial name
- NCT06071013
- Testing
- Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- China Medical University Hospital
Lung Adenocarcinoma, EGFR Activating Mutation
Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations.
- Trial name
- NCT06730477
- Testing
- observational study
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center.
- Conditions
- Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
- Trial name
- PROMISE (NCT07696832)
- Testing
- Ivonescimab Injection
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Guangdong Association of Clinical Trials
Non Small Cell Lung Cancer
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy
Complete surgical resection is the standard treatment in early-stage lung cancer. However, the patients with early resected Epidermal Growth Factor Receptor(EGFR)-mutated lung cancers have high recurrence rate.
- Trial name
- NCT05469022
- Testing
- Neoadjuvant lazertinib
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Konkuk University Medical Center
Lung Cancer Stage III, Mutation
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- NUMER (NCT06563999)
- Testing
- Sunvozertinib, Crizotinib, Pralsetinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer, RET Gene Mutation
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003…
- Conditions
- Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- PROFILE (NCT06109558)
- Testing
- LMV-12(HE003)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally…
- Trial name
- TROPION-Lung14 (NCT06350097)
- Testing
- Osimertinib, Datopotamab Deruxtecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 582 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination…
- Trial name
- NCT06276283
- Testing
- DZD9008 plus Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Dizal Pharmaceuticals
Non-Small Cell Lung Cancer With EGFR Mutation
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under…
- Trial name
- NCT05852990
- Testing
- Glutamine plus L. reuteri
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University